Amarin Stock at $12 a Share? This Analyst Thinks It’s Possible, , on September 29, 2020 at 10:34 pm

By
On September 29, 2020
Tags:

If you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin (AMRN) have been under the cosh this year, as the company has battled its way through the courts to no avail.Amarin lost a patent case, and then its appeal too, against generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s, who have their own plans for versions of Amarin’s high triglyceride treatment Vascepa. Investors have jumped ship in the meantime, sending shares down by a mighty 80% year-to-date.But conversely, if you are looking to pick up some shares on the cheap, SBV Leerink analyst Ami Fadia believes Amarin presents a compelling opportunity.The analyst reiterated an Outperform (i.e. Buy) rating on AMRN shares, while raising the price target from $9 to $12. Investors are looking at hefty upside of 200% from current levels. (To watch Fadia’s track record, click here)While Amarin’s hopes for a U.S. market dominated by Vascepa took a severe blow following the negative ruling, Fadia believes Vascepa’s commercial opportunity lies elsewhere, and is one which the rest of the Street is totally underestimating.“For Vascepa EU sales, we are significantly above consensus (+67% vs consensus for 2023 international sales) and estimate un-risk adjusted peak sales in EU of $2.8B in 2033 driven by 20% penetration in a 9M patient TAM,” Fadia said. “We estimate a TAM in EU5 of ~81% that in the US and believe that Amarin will be able to obtain pricing in EU at parity with the US (we assume 15% discount to US net price). As we get clarity on the EU label through CHMP opinion (likely late 2020) and EMA approval (1Q21), and pricing (in 2021 post approval) we believe the value of the EU opportunity will be better appreciated.”Overall, the EU opportunity makes up three quarters ($9) of Fadia’s price target. The final quarter is made up of $2 from the rest of the world and just $1 in the U.S.Fadia expects Vascepa to retain 65% of the U.S. market in 2021, but believes the generics will improve supply in the long run and “meaningfully erode the market by 2022,” as reflected in the small part the U.S. plays in Fadia’s projected share price.Among Fadia’s colleagues, rating wise, the bulls are slightly in front. AMRN’s Moderate Buy consensus rating is based on 6 Buys and 4 Holds. However, the bulls are out in full force where the average price target is concerned; At $10.70, the analysts expect the stock to change hands for a 165% premium over the next 12 months. (See Amarin stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Amarin Stock at $12 a Share? This Analyst Thinks It’s PossibleIf you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin (AMRN) have been under the cosh this year, as the company has battled its way through the courts to no avail.Amarin lost a patent case, and then its appeal too, against generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s, who have their own plans for versions of Amarin’s high triglyceride treatment Vascepa. Investors have jumped ship in the meantime, sending shares down by a mighty 80% year-to-date.But conversely, if you are looking to pick up some shares on the cheap, SBV Leerink analyst Ami Fadia believes Amarin presents a compelling opportunity.The analyst reiterated an Outperform (i.e. Buy) rating on AMRN shares, while raising the price target from $9 to $12. Investors are looking at hefty upside of 200% from current levels. (To watch Fadia’s track record, click here)While Amarin’s hopes for a U.S. market dominated by Vascepa took a severe blow following the negative ruling, Fadia believes Vascepa’s commercial opportunity lies elsewhere, and is one which the rest of the Street is totally underestimating.“For Vascepa EU sales, we are significantly above consensus (+67% vs consensus for 2023 international sales) and estimate un-risk adjusted peak sales in EU of $2.8B in 2033 driven by 20% penetration in a 9M patient TAM,” Fadia said. “We estimate a TAM in EU5 of ~81% that in the US and believe that Amarin will be able to obtain pricing in EU at parity with the US (we assume 15% discount to US net price). As we get clarity on the EU label through CHMP opinion (likely late 2020) and EMA approval (1Q21), and pricing (in 2021 post approval) we believe the value of the EU opportunity will be better appreciated.”Overall, the EU opportunity makes up three quarters ($9) of Fadia’s price target. The final quarter is made up of $2 from the rest of the world and just $1 in the U.S.Fadia expects Vascepa to retain 65% of the U.S. market in 2021, but believes the generics will improve supply in the long run and “meaningfully erode the market by 2022,” as reflected in the small part the U.S. plays in Fadia’s projected share price.Among Fadia’s colleagues, rating wise, the bulls are slightly in front. AMRN’s Moderate Buy consensus rating is based on 6 Buys and 4 Holds. However, the bulls are out in full force where the average price target is concerned; At $10.70, the analysts expect the stock to change hands for a 165% premium over the next 12 months. (See Amarin stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage